Stryker Corporation $SYK Shares Bought by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 220,211 shares of the medical technology company’s stock after buying an additional 7,546 shares during the period. Clark Capital Management Group Inc.’s holdings in Stryker were worth $77,398,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares during the period. State Street Corp boosted its position in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after buying an additional 311,507 shares during the period. Geode Capital Management LLC boosted its position in shares of Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after buying an additional 69,851 shares during the period. Alliancebernstein L.P. boosted its position in shares of Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the period. Finally, Norges Bank acquired a new position in shares of Stryker during the fourth quarter worth approximately $1,822,272,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. Citigroup reduced their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Truist Financial reiterated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. UBS Group reduced their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $395.33.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $310.71 on Wednesday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock has a market cap of $119.11 billion, a price-to-earnings ratio of 35.96, a PEG ratio of 1.97 and a beta of 0.78. The stock’s 50 day moving average price is $315.51 and its 200 day moving average price is $342.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the previous year, the firm earned $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.